Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Brief, High-dose rTMS for Depression

NCT: NCT04657432 · ACTIVE_NOT_RECRUITING

NCT IDNCT04657432
StatusACTIVE_NOT_RECRUITING
Start Date2021-05-25
Completion2026-12-01

Brief Summary

High frequency repetitive transcranial magnetic stimulation (rTMS) has been shown to be safe, feasible, and acceptable. Conventionally, rTMS investigations have relied on rational decision trees for dosage determination. The purpose of this study is to systematically examine an accelerated protocol of intermittent theta burst (iTBS). Study 1 aims to provide a quantifiable dose-response curve for iTBS and depressive symptom reduction in major depression. Study 2 aims to determine the role of individual variations of their functional networks compared to the site of stimulation and clinical outcomes.

Frequently Asked Questions

What is Brief, High-dose rTMS for Depression?

Brief, High-dose rTMS for Depression is a clinical trial registered under NCT04657432. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT04657432?

The current status of NCT04657432 (Brief, High-dose rTMS for Depression) is: ACTIVE_NOT_RECRUITING.

When did Brief, High-dose rTMS for Depression start?

Brief, High-dose rTMS for Depression started on 2021-05-25.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.